Clinical trials
Autologous Stem Cell Transplantation clinical trials
Below are recruiting autologous stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 214 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT06931613Enrolling by invitationPhase 2
STEM CELL TRANSPLANT FOR HODGKIN LYMPHOMA AFTER NIVOLUMAB
This trial tests a stem cell transplant using your own cells for children and teens with Hodgkin lymphoma that has come back or not gotten better after multiple treatments. It involves using a medicine called nivolumab before the transplant to help your body fight the cancer.
MoscowAges 2–18 - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06861257Recruiting
Treosulfan monitoring in pediatric stem cell transplant
This study watches how the chemotherapy drug Treosulfan works in children getting a stem cell transplant. The goal is to make sure the dose is just right for each child.
Bologna, bOLOGNAAges Up to 18 years - NCT01756365Recruiting
Stem cell eye treatment from your own cornea cells
This trial tests an eye treatment made from your own cornea surface cells, grown in a lab and put back into the eye. It may help people with limbal stem cell deficiency by improving the health of the eye surface after a cell biopsy.
Toronto, OntarioAges 1 year+ - NCT06818916Recruiting
A study of hetrombopag to help platelets recover after stem cell transplant for neuroblastoma
This trial tests if a drug called hetrombopag can help children with neuroblastoma recover their platelet counts more quickly after their own stem cells are transplanted. It aims to reduce the time needed for platelet engraftment and lower the risk of bleeding.
BeijingAges Up to 18 years - NCT06802406Recruiting
Nutrition support for transplant or cell therapy patients
This study tests a program to help patients who are getting a transplant or cell therapy and have trouble getting enough food. It provides nutrition resources to improve their health during treatment.
Stanford, CaliforniaAges 8–80 - NCT06789003Recruiting
Prehabilitation with exercise for multiple myeloma patients
This trial tests whether a prehabilitation program using adapted physical activity can help multiple myeloma patients prepare for a stem cell transplant. It may improve your strength and recovery before and after the transplant.
AvignonAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Birmingham, AlabamaAges 18–75 - NCT01166009Recruiting
CIBMTR research database for transplant and bone marrow injury patients
This study collects health and treatment information in a large research database. It may help researchers better understand outcomes after blood stem cell transplants or bone marrow injury from treatment like radiation.
Minneapolis, MinnesotaAges Any age - NCT06687837RecruitingPhase 1
Stem cell therapy for Parkinson's disease
This trial tests whether implanting your own stem cells (made into dopamine-producing brain cells) can improve Parkinson's motor symptoms. You would need to be a candidate for brain surgery and have a stable medication routine.
Boston, MassachusettsAges 45–80 - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT05827835RecruitingPhase 1/Phase 2
CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Hangzhou, ZhejiangAges 18 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06676852Recruiting
Palliative care support for stem cell transplant patients
This study tests whether adding a palliative care program (extra support for comfort and quality of life) is helpful for people receiving a stem cell transplant. It aims to see if patients and doctors find it useful and easy to use.
Boston, MassachusettsAges 18 years+ - NCT06679829RecruitingPhase 2
Melphalan with or without siltuximab for multiple myeloma stem cell transplant
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
Basking Ridge, New JerseyAges 60 years+ - NCT06575712Recruiting
Coping skills training to manage symptoms and daily steps
This study tests a coping skills training program to help people who have had a stem cell transplant or CAR-T cell therapy for blood cancer manage fatigue, pain, and stress. It may help you feel better and be more active in daily life.
Durham, North CarolinaAges 18–99 - NCT06541002Recruiting
SHIFT app for stem cell transplant survivors' sexual health
This trial tests a mobile app (SHIFT) designed to help people who have had a stem cell transplant and are experiencing sexual health concerns. It aims to see if the app can improve your well-being.
Coral Gables, FloridaAges 18 years+ - NCT06461988RecruitingPhase 2
Talquetamab and lenalidomide after stem cell transplant for myeloma
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Palo Alto, CaliforniaAges 18 years+ - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+ - NCT06377540RecruitingPhase 2
Pembrolizumab plus BEAM with stem cell transplant for Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Minneapolis, MinnesotaAges 18 years+ - NCT06316856RecruitingPhase 1/Phase 2
Targeted immune cell therapy for resistant T-cell cancers
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 1–70
Hear when a new Autologous Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autologous stem cell transplantation?
- Yes. Clin2 currently lists 214 recruiting autologous stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autologous stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autologous stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.